This case suggests that targeting the VEGF/VEGFR signaling pathway may be an essential new therapeutic choice for <i>TFE3</i>-associated malignant PEComas. This evidence concerns the gene VEGFA and neoplasm with perivascular epithelioid cell differentiation.